BioSpace News Archive

Morphic Therapeutic today reported corporate highlights and financial results for the first quarter 2024.

Kymera Therapeutics, Inc. will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET.

Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.

Nanoscope Therapeutics, Inc. announced today the appointment of Allen C. Ho , MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.

Compugen Ltd. today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.

Can-Fite BioPharma Ltd. today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report” (Link).

Onconic Therapeutics today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.

SDS Optic’s inPROBE® marks a pivotal shift in oncology towards personalized medicine, particularly in the assessment of protein expression like HER2. This novel in vivo approach allows the examination with optic fiber probe directly in the patient’s body without tissue extraction.

ProPhase Labs, Inc. today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close.